Drugs / Gag:267-274 peptide vaccine
last change Mar 2017 re-read 2 minutes ago

Gag:267-274 peptide vaccine

Vaccine

Developed for
melanoma
Investigated by
Mayo Clinic · National Cancer Institute (NCI)

Trials 1 · a red edge is where a trial was stopped

201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 0 NCT01748747 Oct 2012 → Dec 2014 melanoma Mayo Clinic Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Gag:267-274 peptide vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT01748747
Modality Vaccine “Gag:267-274 peptide vaccineNCT01748747
Route Subcutaneous “Gag:267-274 peptide vaccine emulsified in Montanide ISA 51 VG subcutaneously (SC)” NCT01748747